Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial-Reference-Cited by-同舟云学术

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial

Published:2021-01 Issue: Volume:143 Page:64-74
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Nabid Abdenour^ORCID,Carrier Nathalie,Vigneault Eric,Van Nguyen Thu,Vavassis Peter,Brassard Marc-André,Bahoric Boris,Archambault Robert,Vincent François,Bettahar Redouane,Wilke Derek,Souhami Luis

Funder

AstraZeneca Canada

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study;Bolla;Lancet Oncol,2010

2. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer;Mason;J Clin Oncol,2015

3. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer;Laverdière;J Urol,2004

4. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial;D'Amico;JAMA,2008

5. Radiotherapy and short-term androgen deprivation for localized prostate cancer;Jones;N Engl J Med,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit;Urologic Oncology: Seminars and Original Investigations;2024-08

2. Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials;Radiotherapy and Oncology;2024-06

3. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer;JCO Precision Oncology;2024-05

4. The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer;The Prostate;2024-03-25

5. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907);International Journal of Radiation Oncology*Biology*Physics;2024-02